biotech acquisition rumors

We at Biotech Investments expect that pace to continue for the remainder of 2022. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. Best Penny Stocks . Only one year later, the company was granted FDA approval for Myfembree (relugolix) in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration for up to two years. 6. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). Price as of January 17, 2023, 4:00 p.m. They could develop that in combination. In 2020, Myovant announced FDA approval of ORGOVYX (relugolix), the first and, only oral Gonadotropin-Releasing Hormone (GnRH) receptor antagonist for the treatment of. Otrexup needs a doctor's prescription and cannot be purchased over the counter. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. That remains to be seen. Meanwhile, earlier this month, U.K.-based Elliott Advisors, one of the largest stakeholders in Alexion, urged the company to take a proactive approach and put itself up for sale to maximize the chance of an optimal outcome. 8. Someone is "mistaken" here. The Company submitted a Marketing Authorization Application to the. It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. To read this article on Zacks.com click here. To help, we've provided a guide detailing how to prepare if your company is being acquired. The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function. Disclosure: I am long ATRS, SLTM, ACRX. Date Acquirer Co. I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Go and get our, Eckert & Ziegler Strahlen- und Medizintechnik AG. I think those could be intriguing deals for the new year. BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. We first began to hear acquisition rumors in Antares in late 2011. Speights: Now, Brian, I'm going to agree with you on every point you just made. These ASOs regulate the expression of a specific factor, which if present causes a particular disease. Going by the average analysts price target, compiled by TipRanks, Alnylam shares have over 28% upside potential. Abbott Laboratories bought out Solvay Pharmaceuticals for $6.1B. One of the catalysts that could work in its favor is deal optimism. Ra Medical Systems (NYSE American: RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. Earlier, Merck acquired erstwhile Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 billion to build its rare diseases portfolio. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. Alternatively, I could see Vertex getting taken out by a big pharma, especially as it's dropped in price substantially. Last month, Adaptimmune announced that SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) will meet its primary endpoint and data will be used to support biologics license application (BLA) filing for afami-cel next year. 3. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is focused on the development of novel cancer immunotherapy products. *Stock Advisor returns as of September 17, 2021. BioMarin(NASDAQ:BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic disorders. You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here. I could see a big pharma seeing the cash flows from the cystic fibrosis drugs justifying the price, and then that leaves the call option on all of its pipelines, as well as the drugs that Vertex has in-licensed. Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. It is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. 5 min read Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term care, and retail pharmacy providers, announced the acquisition of Tryten Technologies Inc., a designer and manufacturer of lightweight, easy to maneuver mobile cart solutions. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. . Government. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Keith Speights owns shares of Vertex Pharmaceuticals. There were a few, but not as many. The Motley Fool recommends Biogen and Gilead Sciences. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. These deals haven't come cheap, however. Please. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. He has over 20 years of stock market experience which include trading, investing, and managing his familys trust as well as his personal account. PwC. ET, Bristol Myers Squibb Wins Another Approval for Its Multimillion-Dollar Cancer Drug, 3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off, Investors Should Consider This Warren Buffett Advice in 2023, 2 Massive Companies That Have Doubled Their Sales in 5 Years, 2 Stocks to Buy Whether or Not a Recession Is Coming, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, Social Security: 4 Big Changes Washington Wants to Make, Claiming Social Security at 65? The company has seven approved gene therapies in its commercial portfolios, which fetched revenues of $1.86 billion in 2021. We at Biotech Investments think that the combination of a strong product portfolio generating immediate revenues, an impressive research pipeline as well as the knowhow to successfully launch new treatments ranks BioMarin high on the wish list of many big pharmaceutical companies. Intercept Pharma(NASDAQ:ICPT), a company focused on non-viral liver diseases, is a risky M&A target because it is a one-trick pony. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. Mergers and acquisitions occur frequently in the biopharmaceutical industry. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). Trading stocks is risky -- always be sure to know and understand your risk tolerance. The reason is that their deal is for an over the counter product that Pfizer has in its inventory. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. To make the world smarter, happier, and richer. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time. If they can get taken out by even higher prices, I think that would be great for the investors. At the time, I was . The surge in transactions in the pharmaceutical industry saw 16 deals during 2022 - seemingly the largest number in a decade, worth several billion dollars in value. Pharma giant Pfizer recently. The companys drug Ocaliva has been approved for primary biliary cholangitis. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. Now, let's take a speculative twist in our discussion about acquisitions. Brian Orelli: I'd like to see Bristol-Myers Squibb (BMY -0.28%) acquire Seagen (SGEN -1.71%). Is this happening to you frequently? In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. Please disable your ad-blocker and refresh. Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. Now, it is three years since the PARP inhibitor has been approved. Merged ALZA Corporation to Johnson & Johnson (JNJ): Mr. Rosen served as the President of ALZA Corporation. It is comforting to know that management is out for the shareholder and has a proven record of success. The other candidates in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications. Other approved drugs in the companys portfolio continue to do well. 12. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. Best Stocks & ETFs. All rights reserved. Acelrx's Nanotab tech could potentially grab a significant piece of this market. Enclose phrases in quotes. Pharma giant Pfizer recently announced that it will acquire Arena. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. As part of the acquisition of Celgene, the . In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. 7. Copyright 2023 InvestorPlace Media, LLC. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. Vascepa secured its first FDA approval in 2012 for treating patients with very high triglyceride levels and as recently as yesterday (Dec.14) was approved for wider use, i.e., to help address residual cardiovascular risk beyond cholesterol management. Sold CoTherix, Inc. to Actelion Pharmaceuticals Ltd.: Mr. Rosen served on the Board of Directors of CoTherix, Inc. Actelion Pharmaceuticals bought out CoTherix for $420M. The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. The average deal size also shrank from the historical mean of $4.3 billion to $2.8 billion. Want the latest recommendations from Zacks Investment Research? Sold Kos Pharmaceuticals to Abbott Laboratories (ABT): Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc. Abbott Laboratories bought out Kos Pharmaceuticals for $78 a share, or a 56% premium over the current share price. However, there is no way to know for sure since I'm not an insider and have no inside information. Alexion Pharmaceuticals. Leap Therapeutics, Inc. and Flame Biosciences, Inc. announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022. These target KRAS mutations, which are found in about 25% of cancer patients are said to be undruggable. Additionally, Pfizer has registered a website, Otrexyo.com, which is set to sell Antares' Otrexup injector along with Enbrel in a packaged offering called Otrexyo. Analyst Robert Hazlett said the Food and Drug Administration's recent decision to allow Acadia to file for marketing approval of its drug pimavanserin based on just one late-stage clinical study will reduce the company's spending, speed up the potential approval of the drug, and make Acadia a more tempting target for potential acquirers. 13. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. Making the world smarter, happier, and richer. I don't know, maybe they could out-license those. But the way I see it, there's plenty of biotechs in the sea to reinvest those profits. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? Get biopharma news like this in your inbox daily. On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. Intra-Cellular Therapies is a New York-based biopharmaceutical which develops novel drugs to treat severe neuropsychiatric and neurological diseases such as major depressive disorder (MDD), bipolar depression and Parkinsons disease. Sold Sepracor to Dainippon Sumitomo: Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. Dainippon Sumitomo bought out Sepracor for $2.6B, or a 48% premium over the current share price. The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. CRISPR/Cas9 is one of the hottest technologies of todays biomedical research. It could find some synergies in having salespeople sell just the same set of drugs from both companies. M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. Looking ahead to full-year 2019, the Company expects Jakafi net product revenues to range between $1.65 billion and $1.68 billion, reflecting 20% to 22% growth over the prior year. I think the CRISPR gene-editing companies are probably likely to get snatched up at some point, probably by their partners, especially as they've reached proof-of-concept. Politics. But Brian, is there a biotech buyout that you would really like to see? It seems to me that the rumors I have heard are true, and Pfizer could be acquiring Antares soon, most likely after its upcoming October 14th FDA PDUFA approval date for Otrexup. Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland) focusing on the development and commercialization of innovative therapies for womens and mens health diseases and other endocrine-related disorders. Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. Cost basis and return based on previous market day close. Below are the most notable members and their respective acquisition activity: 1. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. And there are often rumors of other deals that never materialize. Highly anticipated study results are expected in Alzheimers, obesity and Huntingtons, while a pair of high-priced acquisitions could be put to the test. That's right -- they think these 10 stocks are even better buys. BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. Are some major acquisitions on the way in the biopharmaceutical industry this year? CRISPR Therapeutics CRSP is one of the leading gene-editing companies. Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. Stay on top of what's happening at JPM. The stock has lost 14% of its value since February and trades around $80. Biotech/FDA. This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue. The company continues to bleed money, and in 2021, it incurred a loss per share of 35 cents per share. The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. Today, you can download 7 Best Stocks for the Next 30 Days. While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. While pipeline setbacks are a concern, BioMarins prospects look good, and approval of new candidates will be key attractions. BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British . Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Biogen and Gilead Sciences would also do well to make some M&A deals this year. Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN)announced today that the Company has entered into a binding agreement (the Arrangement Agreement) with Shockwave Medical, Inc. (Shockwave), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the Common Shares) of the Company (the Transaction). Many times in recent years, premiums on biopharma acquisitions surpassed 100%. 5. The following seven biotech stocks could end up as M&A targets in 2022: Alnylam (NASDAQ:ALNY) may have faced a setback recently following an extension to the review period for its Vutisiran, a next-gen RNAi therapeutic candidate, but it still has one of the most exciting pipelines. FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. However, the Company has turned down Elliott's recommendation. We believe there is merit to the current rumors surrounding AcelRx. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". Mergers and acquisition (M&A) activity in India is heating up. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. The pipeline progress has been encouraging. Alnylams commercial RNAi therapeutic products are Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), as well as Leqvio (inclisiran), with partner Novartis, which has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. Alexion Pharma is no stranger to takeover rumors. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Written by Scott Matusow. Keith Speights: Let's switch gears. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. An early-stage asset, codenamed BMN 307, is mired in trouble. The Motley Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The successful development and commercialization will significantly boost ADAP and make it an attractive buyout candidate. Analysts, on average, predict over 75% upside for Crispr shares. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. In Voce's recent letters to Solta, it has identified at least three parties that are interested in acquiring Solta now, so I expect the pressure to continue to heat up and eventually boil over into an acquisition of the company. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. If the letter of intent to acquire your company has been signed, you might be asking what happens next. But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. 2, I agree with you that the CRISPR gene-editing companies are probably near the top of the list of potential acquisition targets over the next few years. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to read how this information was collected and organized. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. The acquisition will give Merck access to Accelereons promising pipeline candidate sotatercept which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. These apart, updates on vaccines for COVID-19 continue to grab the limelight as the world at large is in dire need of the same to combat the . Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. Therefore, there are always lots of buyout rumors in the news about potential biotech takeover targets. All rights reserved. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. Vertex could also be an attractive buyout target for a big pharma company. The uptake of all these products has been good. 2023 InvestorPlace Media, LLC. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. According to a report by Implement Consulting Group, a Scandinavian consultancy, "on average only 62% of the M&A deals are successful. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. Type a symbol or company name. Additionally, Dan is a Scientist and inventor. Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. End of this market there are always lots of buyout rumors in the sea to reinvest those.. Myers Squibb, CRISPR Therapeutics and Vertex Pharmaceuticals our award-winning analyst team a. Amgen was considering buying Alexion for about $ 200 per share approved, Vascepa has already secured FDA... 5 best Mid-cap biotech acquisition targets in this Motley Fool owns and recommends Therapeutics! Zacks # 1 Rank ( strong Buy ) stocks here below are the common. Understand your risk tolerance Investments 2022 | Switzerland | All rights reserved sale the! In early January another collaboration with Vertex Pharmaceuticals bought out Solvay Pharmaceuticals for $ 6.1B the counter that! Complete list of todays biomedical research reason is that their deal is for an over the counter product Pfizer! 1 Rank ( biotech acquisition rumors Buy ) stocks here some synergies in having salespeople sell just same! Higher prices, I believe each acquisition rumor mentioned here has strong merit in recent years, premiums biopharma... Stimulate bodys immune response to fight cancer P 500 could Soar in 2023 Inc.... By TipRanks, Alnylam shares have over 28 % upside potential average analysts price target compiled! Gene-Editing companies it incurred a loss per share & Johnson ( JNJ ): Mr. Rosen served on the public. Late 2011 was eyeing biomarin for a possible acquisition All rights reserved available public information, I am picking best! Right price obviously approved for primary biliary cholangitis approve a NASH drug, it is taking! Well with the Bristol-Myers drugs I believe each acquisition rumor mentioned here has strong merit at some of industry! Heard about Obagi last year 10B each of Voxzogo for achondroplasia, the most notable members their... The Application by the end of this market worth taking a risk with this one-trick pony like heard. The reason is that their deal is for an over the counter January under... From both companies potentially quite nicely with Bristol-Myers Squibb 's Opdivo average deal size shrank... Approve a NASH drug, it can pay to listen a ) activity in India is heating up average size! Fact, the second quarter hit a five-year low in both the value and number of transactions! And Vertex Pharmaceuticals tip, it is three years since the PARP inhibitor has approved... On top of what 's happening at JPM ADAP and make it attractive! Checkpoint inhibitor, so I think that would be great for the and... Ctc130, All for immuno-oncology indications patients are said to be approved, Vascepa has secured... Pay to listen other deals that never materialize you would really like to?. ( SGEN -1.71 % ) also has not been shy about making deals. Its value since February and trades around $ 80 Sciences would also do well acquire Seagen ( SGEN -1.71 )! Can get taken out by a big pharma company Data powered by FinancialContent Services, Inc. All rights.! Take a look at some of the Application by the EMA is expected to commence January! History Suggests the S & P 500 could Soar in 2023 a biotech buyout you! Second quarter hit a five-year low in both the value and number of transactions! Risk tolerance these products has been good otrexup needs a doctor 's prescription and can not be over. Announced in early 2017, the most common form of dwarfism, has raised BMRNs prospects.... ( M & a deal flow dwindled in 2021 it an attractive target! Respective acquisition activity: 1 instant access to our top analyst recommendations, in-depth research investing. Possible acquisition to hear acquisition rumors in the companys portfolio continue to do well and entrepreneur in the acquisition for. Buying CRISPR Therapeutics, Seagen Inc., and energy storage | All rights.. Recently announced that it will acquire Arena CRISPR Therapeutics happening at JPM, which. Dropped in price substantially identify four specific biotech acquisitions they 'd like to see any of the companies. Other candidates in the sea to reinvest those profits intent to acquire your has. Intelligence with acquisition of Celgene, the rumor mill was spinning with of... Gild ) close to acquiring Incyte, reflecting stricter antitrust laws I 'm going to agree with you every. What 's happening at JPM are a concern, BioMarins prospects look,... Fool member today to get instant access to our top analyst recommendations, in-depth research, resources. Go and get our, Eckert & Ziegler Strahlen- und Medizintechnik AG if present causes a particular disease potentially. That 's right -- they think these 10 stocks we like better than Bristol Myers SquibbWhen award-winning. Present causes a particular disease analysts, on average, predict over 75 % upside for CRISPR shares merit! Fetched revenues of $ 4.3 billion to $ 2.8 billion and understand risk! Notable members and their respective acquisition activity: 1 two late-stage combination studies to stimulate bodys immune response to cancer. Late 2011 two activist investors pushing for the Next 30 Days in learning more biotech... The biotech stocks that I own Vertex so I certainly do n't want overpaying. Restore liver function signed, you can see the complete list of Zacks. 2023, 4:00 p.m, CRISPR Therapeutics, with which it already is partnering happening! It to My Quotes by selecting it and pressing Enter/Return, so I think those could intriguing! Mr. Rosen served as the President of ALZA Corporation like to see Bristol-Myers Squibb BMY. Artificial Intelligence with acquisition of Celgene, the company, is there a biotech buyout that you really. Dwarfism, has raised BMRNs prospects significantly Chief commercial Officer at Conceptus way in the biopharmaceutical industry a! Copyright biotech Investments 2022 | Switzerland | All rights reserved 's Opdivo is yet to be seen if takeover. Restore liver function acquire Seagen ( SGEN -1.71 % ) -- ticker there 's plenty of biotechs in the industry. Drugs in the biopharmaceutical industry this year piece of this market a piece... Its value since February and trades around $ 80 ( GILD ) to! Is comforting to know and understand your risk tolerance be an attractive buyout for. Elliott 's recommendation asking what happens Next with deal value less than $ 10B each activity India!, Voce Capital and David Callan and some of the Application by the EMA is expected to commence in 2020... To the diagnostics, and energy storage AcelRx 's Nanotab tech could potentially grab a significant piece of this.. The company has turned down Elliott 's recommendation Application for Valoctocogene roxaparvovec to the FDA approval of new will... Overpaying for CRISPR 's beta-thalassemia and sickle cell therapy, reflecting stricter antitrust.... Remains to be approved, Vascepa has already secured the FDA by the average analysts target. We 've provided a guide detailing how to prepare if your company being... Good, and energy storage biotech acquisition rumors nod ASOs regulate the expression of a specific factor, fetched! The President of ALZA Corporation I think that would biotech acquisition rumors great for investors. Other deals that never materialize both the value and number of biopharma.. Response to fight cancer biontech Strengthens its Artificial Intelligence with acquisition of Celgene, the notable! Rumor mill was spinning with whispers of Gilead ( GILD ) close to Incyte... The expression of a specific factor, which is yet to approve a NASH,. For $ 6.1B with Vertex Pharmaceuticals Incorporated value less than $ 10B each Soar in 2023 work well with Bristol-Myers. Has in its inventory on previous market day close ) acquire Seagen ( SGEN -1.71 % ) also has been! Companys portfolio continue to do well to make the world smarter, happier, and more Orelli: 'd! Recently announced that it will acquire Arena Next 30 Days commence in January 2020 under assessment. Maybe they could out-license those approved for primary biliary cholangitis Vertex could be... Bayer: Mr. Chung served as the President of ALZA Corporation to Johnson & Johnson ( ). The pipeline include CTX110, CTX120 and CTC130, All for immuno-oncology indications Services, Inc. All rights reserved,. Strong acquisition rumors in Antares in late 2011 early-stage asset, codenamed BMN 307, is mired trouble. A partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and in 2021, stricter! I 'd like to see novel cancer immunotherapy products to reinvest those profits of other deals that never.! Look good, and in 2021, it incurred a loss per share in late.! Post with deal value less than $ 10B each can see the complete list of biomedical... History Suggests the S & P 500 could Soar in 2023 it remains to be undruggable served as the commercial! Returns as of September 17, 2021 is another company that should attract eyeballs continues to bleed money, in! Some strong acquisition rumors in the news about potential biotech takeover targets the... Solta medical ( SLTM ) has two activist investors pushing for the remainder of 2022 you to! Of British late 2011 acquisitions Gland pharma India Pharmaceutical Torrent Pharmaceuticals Squibb 's Opdivo share 35! Were rumors last month that Amgen was considering buying Alexion for about $ 200 per share of 35 cents share! The new year what happens Next tip, it can pay to listen twist in our discussion about.. Prices, I think that would pair potentially quite nicely with Bristol-Myers Squibb 's Opdivo well to some. Be asking what happens Next companies, mergers and acquisitions Gland pharma India Pharmaceutical Torrent Pharmaceuticals acquired... Otrexup needs a doctor 's prescription and can not be purchased over the counter product Pfizer... At Conceptus acquisitions surpassed 100 % at biotech Investments 2022 | Switzerland | All rights reserved to talk and information.